Viral Vaccine Purification Process
Downstream processing for viral vectors — clarification, ultrafiltration, chromatography, and ultracentrifugation for influenza, adenovirus, and AAV vaccines
Process Overview
Viral vaccine purification recovers infectious virus particles from cell culture harvest. The process must remove host cell proteins, nucleic acids, empty capsids, and adventitious agents while maintaining viral integrity and immunogenicity. Different vaccine platforms (influenza, adenovirus, AAV) share common purification steps but differ in specific requirements.
Process Steps
1
Clarification
Cell Harvest & Primary Clarification
Harvest virus from cell culture by centrifugation (for cell-associated viruses) or direct harvest from supernatant (for secreted viruses). Depth filtration (0.45–0.65 μm) removes cells and large debris. For adenovirus and AAV, cell lysis may be required before clarification.
Yield: >90%
Removes: Cells, debris
2
Concentration
Tangential Flow Filtration (TFF)
Concentrate and partially purify virus using ultrafiltration membranes (MWCO 100–750 kDa depending on virus size). Influenza: 100–300 kDa; Adenovirus: 750 kDa; AAV: 100–300 kDa. Buffer exchange into loading buffer simultaneously. Typical concentration factor: 10–50×.
Yield: 85–95%
Volume: 10–50× reduction
3
Chromatography
Ion Exchange or Affinity Chromatography
For adenovirus: Anion exchange (Q Sepharose) captures virus at low salt. Elute with 300–500 mM NaCl. For AAV: Affinity chromatography (heparin or AVB Sepharose) captures capsids. For influenza: Sucrose gradient or membrane-based purification.
Yield: 60–80%
Purity: 70–90%
4
Polishing
Gradient Ultracentrifugation or Chromatography
CsCl gradient: For AAV and adenovirus, separates full from empty capsids based on density (1.39 vs 1.31 g/mL for AAV). Sucrose gradient: For influenza, separates intact virions from defective particles. Alternative: Multimodal chromatography for scalable polishing.
Yield: 50–70%
Purity: >95%
5
Viral Clearance
Nucleic Acid Removal & Inactivation
Remove residual nucleic acids by benzonase or DNase treatment followed by chromatography. For inactivated vaccines (influenza), add β-propiolactone or formaldehyde. For live attenuated vaccines, downstream inactivation is not required but sterility testing is critical.
Yield: >95%
DNA: <10 pg/dose
6
Formulation
Final Ultrafiltration & Sterile Filtration
Diafilter into final formulation buffer (PBS, trehalose, polysorbate 80 for stability). Concentrate to final dose volume. Sterile filter through 0.22 μm membrane. Fill into vials or syringes under aseptic conditions.
Yield: >95%
Sterility: 0.22 μm filter
Vaccine Platform Comparison
| Platform | Virus Size | Key Challenges | Primary Capture | Polishing |
|---|
| Influenza | 80–120 nm | Egg vs cell-based, HA/NA balance | sucrose gradient | Zone sucrose gradient |
| Adenovirus | 90–100 nm | Empty capsids, high viscosity | Anion exchange | CsCl gradient or multimodal |
| AAV | 20–25 nm | Empty/full capsids, serotype differences | Affinity (heparin/AVB) | CsCl or iodixanol gradient |
Cost Considerations
| Step | Key Cost Driver | Relative Cost |
|---|
| Clarification | Depth filters, centrifugation | Low–Medium |
| TFF Concentration | Membrane cassettes, buffer | Medium |
| Chromatography | Resin, column hardware | High |
| Ultracentrifugation | Equipment depreciation, consumables | High |
| Sterile Filtration | 0.22 μm filters | Low |
Chromatography and ultracentrifugation dominate costs. For AAV and adenovirus, affinity chromatography significantly improves yield but increases cost. Continuous ultracentrifugation and membrane-based purification are emerging alternatives. Use
untangle.bio to model costs at your specific scale.
Frequently Asked Questions
How do you separate full from empty AAV capsids?
Empty capsids (packaging only DNA, density ~1.31 g/mL) are separated from full capsids (packaging genome, density ~1.39 g/mL) by density gradient ultracentrifugation in CsCl or iodixanol. Empty capsids band at a lower position. This is critical because empty capsids are immunogenic but non-infectious, reducing vaccine efficacy.
What is the main difference between influenza vaccine purification in eggs vs cells?
Cell-based influenza (MDCK cells) produces virus in suspension culture without egg proteins, reducing allergy risk for egg-allergic individuals. Cell-based purification is simpler (no egg proteins to remove) but requires different cell culture optimization. Both pathways use sucrose gradient for final purification.
Can membrane chromatography replace traditional chromatography for vaccines?
Yes, for certain vaccines. Membrane chromatography (with anion or cation exchange ligands) offers faster processing, lower buffer volumes, and lower cost for preliminary capture steps. However, it has lower resolution than resin chromatography, making it better suited for capture rather than final polishing.
Build Your Vaccine Purification Process
Drag-and-drop the full vaccine purification train, simulate mass balance, and estimate manufacturing costs.
Open untangle.bio